Creating new HIV vaccines using targeted nanoparticles
Development and characterization of germline-targeted nanoparticle immunogens toward a novel HIV Env epitope
This study is exploring a new way to create vaccines for HIV by using tiny particles to help your immune system make powerful antibodies that can fight the virus, with the hope of improving prevention and treatment options for people living with HIV.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11013783 on NIH RePORTER |
What this research studies
This research focuses on developing innovative vaccines for HIV by targeting a specific part of the virus known as the 'silent face' of gp120. The approach involves using nanoparticles to elicit broadly-neutralizing antibodies (bnAbs) from the immune system, which could potentially prevent HIV infection. By studying how these antibodies can be produced from different genetic backgrounds, the research aims to create a more effective vaccine strategy. Patients may benefit from advancements in HIV prevention and treatment through this novel approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk of HIV infection or those living with HIV who may benefit from new preventive strategies.
Not a fit: Patients who are already effectively managing their HIV with existing treatments may not see direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective HIV vaccine that significantly reduces the risk of infection.
How similar studies have performed: Previous research has shown promise in developing vaccines targeting similar viral epitopes, indicating potential for success in this novel approach.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Carter, Josh — Stanford University
- Study coordinator: Carter, Josh
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.